Fig. 5From: Association of metformin monotherapy or combined therapy with cardiovascular risks in patients with type 2 diabetes mellitusCardiovascular mortality among patients with metformin vs. placebo; and combination vs. placebo. Metformin treatment has no meaningful actions on cardiovascular mortality versus control, with a high heterogeneity. However, metformin in combination increases the cardiovascular mortality versus metformin aloneBack to article page